Hot Jobs Report Crashes Tech, Nine-Week Win Streak Ends, and Bonds Spike

Trump posted that with a jobs report this strong, stocks "should go up, not down." The Nasdaq went down anyway, falling nearly 4% as investors processed that 172,000 May payrolls means the Fed is in no hurry to cut and may actually hike. Nine weeks of consecutive gains ended. Today's newsletter covers every name that mattered.

His official paycheck? $400,000 a year.

But the real story is somewhere else:

As much as $250,000 per month… from a single source.

It’s not real estate.
It’s not the stock market.

So what’s actually producing this level of cash flow — and why are more investors turning to it today?

Discover how to get started for less than $20.

A diagnostics stock sitting near a fresh 52-week high just saw insiders sell nearly $8 million, including a large CEO sale tied to an option exercise. Meanwhile, a beaten-down consumer name saw a director buy more than $2.1 million of stock over four straight days. You’re seeing two very different insider signals. Insider readers are seeing where executives are cashing in strength and where one director is buying weakness.

Every day, insiders and institutions move millions before the market catches on. We surface the data behind those moves before the rest of the market sees it.

A subscription gets you:

$25/mo or $250/yr. 30-day money back guarantee. Cancel anytime. Founding member pricing: lock in $25/mo before we raise it.

A May jobs report that came in at 172,000 payrolls, more than double the 80,000 estimate from economists, sent bond yields spiking past 4.5% and flipped the rate narrative from "cuts coming" to "hikes possible" within minutes of the data dropping.

Rate hike probability jumped to nearly 70% on CME futures, and tech names took the hardest hit because high bond yields compress the value Wall Street assigns to companies whose big profits are years away.

The Nasdaq posted its worst weekly decline in over a year, snapping nine consecutive weeks of gains, with Nvidia down 6%, Broadcom down another 7%, and Micron, Marvell, Qualcomm, and AMD all falling 9% or more.

Transportation stocks were the rare bright spot, with Union Pacific, FedEx, and J.B. Hunt all gaining on the logic that a strong jobs market means strong freight volumes.

Tesla (NASDAQ: TSLA) is facing another major company challenge in Quebec, where a new class-action lawsuit alleges that heat pumps in several Tesla models can fail prematurely in cold weather.

The case targets vehicles sold across recent model years and raises concerns about cabin heating, defrosting, repair costs, and winter reliability.

For Tesla, this is not just a regional legal problem. It hits directly at the company’s global EV promise because electric vehicles must prove they can work reliably in tough climates, not just in ideal conditions.

Cold Weather Is a Real Test

Tesla sells itself as a company built for the future of driving. In markets like Canada, Norway, and northern U.S. states, that future still has to survive snow, ice, and freezing mornings.

The issue matters because you do not need a legal degree to understand the business risk. If heating and defrosting become recurring complaints, the conversation moves from comfort to trust.

Not the Right Moment for More Friction

Tesla is trying to defend its lead as global automakers roll out more electric models. Every reliability headline gives rivals another opening to argue that their EVs are safer, steadier, or easier to own.

For a company built on confidence, timing makes this sting more.

If Tesla wants to keep premium trust in colder markets, you should expect the company to face pressure to prove its vehicles can handle real-world conditions without turning ownership into a repair battle.

BioCardia (NASDAQ: BCDA) just received important FDA confirmation that its ongoing CardiAMP Heart Failure II Trial may support a future approval pathway for its heart failure therapy system.

That gives the company a clearer regulatory route for a treatment aimed at patients with ischemic heart failure, a serious condition where new options are still badly needed.

For BioCardia, this is a major company moment because small biotech firms live or die by clinical progress and regulatory clarity.

A defined pathway does not guarantee approval, but it provides the business with a stronger foundation to move forward.

FDA Clarity Changes the Setup

BioCardia now has a better understanding of what the agency expects from its heart failure program.

That matters because uncertainty can slow everything down, from trial planning to funding conversations to future commercial preparation.

For you, the simple business point is that BioCardia is no longer just pushing a hopeful therapy through the clinic. It now has a clearer path to proving whether the product can become real.

Heart Failure Is a Serious Market

The company operates in a disease area where patients need more treatment options. Heart failure is complex, costly, and difficult to manage, which makes any credible new therapy program worth watching.

If the therapy continues to progress, your attention shifts to whether the company can translate clinical validation into a real cardiovascular business.

BioCardia still has to deliver the data needed to support approval. The FDA pathway gives the company a better shot, but execution now becomes the whole story.

Find Elon Musk's next big launch and grab yourself an early stake, before the mainstream catches on and it becomes impossible to make huge gains.

Tesla soared 20,000% over 15 years.

xAI grew 250X in two years.

SpaceX has made early backers 2,000X their money since 2010.

Today, we're revealing Elon's NEXT big launch.

*This ad is sent on behalf of InvestorPlace Media at 1125 N. Charles Street, Baltimore, Maryland 21201. If you're not interested in this opportunity, please click here.

JPMorgan Chase (NYSE: JPM) is joining other major U.S. banks to build a new digital payment network that could allow bank-backed dollars to move instantly while keeping that money within the regulated banking system.

For JPMorgan, this is a major company move because it puts the bank directly in the race to shape the future of digital payments.

Instead of letting stablecoin companies control the next version of fast money movement, JPMorgan is helping build a bank-led alternative.

Banks Want the Digital Dollar Back

Stablecoins showed customers that money can move faster than old banking rails.

JPMorgan and other banks are now responding with a system that maintains speed while adding bank oversight, familiar protections, and institutional control.

Put simply, you are not looking at a crypto side project. JPMorgan is helping to build a new payments layer that could keep large corporate funds moving through banks rather than outside them.

JPMorgan Wants the Center Seat

JPMorgan already has deep experience in institutional payments, and this network provides another avenue to expand that role.

The bank wants to be where major money movement happens, whether the rails are traditional or digital.

If this system gains traction, you get JPMorgan helping to define how regulated digital dollars move in the next era of finance, rather than just reacting to what crypto companies have already built.

Hurco makes CNC machine tools for precision manufacturing and is bouncing on the same logic lifting industrials today: a strong jobs report means strong manufacturing activity, and manufacturing activity means machine tool orders.Up 5.84x relative volume on no specific company news. Sometimes the macro is the whole catalyst.

Merlin Inc. [MRLN] $8.60 (+19.78%)

Merlin makes autonomous flight software for drones and is running today as defense names defy the broader tech selloff. Presenting at the ROTH London Conference next week, and up significantly from its May 28 close. In a session where tech is being sold indiscriminately, Merlin is one of the few where the specific thesis is outrunning the macro.

Cooper Companies [COO] $67.34 (+8.58%)

Cooper Companies makes contact lenses and women's health devices, and beat Q1 EPS estimates with strong CVI contact lens revenue while raising full-year guidance. In a session where macro concerns are overwhelming earnings, COO is one of the names where the actual results are winning the argument. The healthcare sector is catching more defensive flows today.

Planet Labs [PL] $32.22 (-25.98%)

Planet Labs beat Q1 earnings but disclosed a $1.5 billion at-the-market stock offering on the same day. Dilution on top of margin guidance that disappointed, on top of a rate-spike selloff that compresses satellite imaging multiples, is three problems at once. The earnings beat was real. It just had no chance today.

Lululemon [LULU] $114.23 (-8.56%)

Lululemon cut its full-year outlook and issued a weak Q2 guide, with CEO Calvin McDonald citing challenges in the U.S. business, a lackluster response to new products, and a "spike in negative commentary around the brand." Down 40% year-to-date before today, the stock is trading at roughly 10x trailing earnings with real free cash flow. The turnaround story is still in the requiring-evidence phase.

Quantum Corporation [QMCO] $12.70 (-19.52%)

Quantum storage ran hard on AI infrastructure tailwinds and is now getting repriced in a session that is punishing high-multiple tech names without mercy. No fresh Quantum-specific negative news. The guidance was revised positively just three days ago. Today is macro catching up to a name that got a little ahead of itself.

Starlink — Elon Musk’s fast-growing satellite internet venture — is reportedly gearing up for a $100 billion IPO.

To put that in perspective: that’s 228X larger than Amazon’s IPO.

Legendary investor James Altucher is now revealing how everyday investors could position themselves before it hits the public market — for under $100.

He’s even giving away a FREE ticker symbol for those ready to move early.

Click here to access it now.

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.